Skip to main content
European Commission logo print header

Assessment of Zoan products as biomaterials for 3D printing in health care

Project description

3D printing using marine coral

3D printing technology is a rapid emerging technology that empowers manufacturers in the medical sector to produce customised medical equipment and products. Zoan Biomed, a dynamic SME based in the west coast of Ireland, specialises in cultivating medical-grade marine coral and creating products from it that can be used as a bone graft substitute. Zoan, through the EU-funded InnovationOrigin project aims to pen up a new realm of potential applications through the 3D printing sector. Zoan is positioning itself to enter the global 3D printing market, which was valued at USD 4.2 billion in 2014, and is projected to reach USD 44.4 billion by 2025, registering a CAGR of 21.8 % from 2019 to 2025.

Objective

Zoan BioMed is a dynamic SME based in the West coast of Ireland. Zoan has turned to nature, specifically the Ocean, for the blueprints to solve a major biomedical challenge. Zoan specialises in cultivating medical-grade marine coral and creating products from it that can be used as an Orthobiologic scaffold, for use as a bone graft substitute.
With the development of the InnovationOrigin Project, Zoan seeks to adapt and develop platform products as a material for use in 3D printers, to open up a new realm of potential applications for our products and in doing so create a significant market demand in new value chains. The development of 3D printing is now an exciting reality which provides enhanced career growth opportunities for each new generation of engineers and manufacturers entering the workforce. Furthermore, 3D printing technology is a rapid emerging technology which empowers manufacturers in the medical sector to produce customised medical equipment and products. If the project is successful, Zoan will be then in a position to enter the global 3D printing market which was valued at $4.2 billion in 2014, and is projected to reach $44.4 billion by 2025, registering a CAGR of 21.8% from 2019 to 2025.
The Innovation Associate will act as a catalyst, driving our innovation strategy in 3D printing forward and aligning with our business targets of growing capacity on site, building a vibrant hub of employment in a remote part of Connemara and bringing the biomimetic potential of our bio-material to a number of sectors.
Zoan will provide to the Innovation Associate with the opportunity to co-create their own future by helping to develop a new dimension to our business which they can champion and drive forward through defining new innovation projects and partnerships, making them an integral part of our team and providing them with a rewarding career in our company.

Call for proposal

H2020-INNOSUP-2018-2020

See other projects for this call

Sub call

H2020-INNOSUP-2019-02

æ

Coordinator

ZOAN BIOMED LIMITED
Net EU contribution
€ 114 687,50
Address
An luslann kylebroughlan moyculle
H91 TXV5 Galway
Ireland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ireland Northern and Western West
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 0,00